Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza A virus subtype H1N1 hemagglutinin, recombinant
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Influenza A virus subtype H1N1 hemagglutinin, recombinant is a laboratory-produced form of the viral surface glycoprotein hemagglutinin (HA) from the H1N1 strain of Influenza A. Hemagglutinin is essential for viral entry into host cells by binding to sialic acid-containing receptors on the cell surface and mediating membrane fusion during endocytosis. Recombinant forms are typically produced in mammalian or insect cell systems and are used as antigens in research, diagnostics, and vaccine development. The mechanism of action involves mimicking natural HA to elicit an immune response or serve as a target for neutralizing antibodies[2][4][5]. It plays a major role in determining host range restriction and virulence[2]. Recombinant HA proteins have been used in clinical trials for influenza immunization[3].
- Other names
- Influenza A H1N1 hemagglutinin recombinantRecombinant influenza A H1N1 hemagglutinin proteinHemagglutinin HA
02
Targets
SA (Sialic acid)
Beyond the preview
Go deeper on Influenza A virus subtype H1N1 hemagglutinin, recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A virus subtype H1N1 hemagglutinin, recombinant.